Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

NCT02061085 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
53
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

MedSIR